Olivier D Christophe

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6740736/publications.pdf

Version: 2024-02-01

70 papers	2,850 citations	186209 28 h-index	175177 52 g-index
72 all docs	72 docs citations	72 times ranked	3238 citing authors

#	Article	IF	Citations
1	Development of a dual hybrid AAV vector for endothelial-targeted expression of von Willebrand factor. Gene Therapy, 2023, 30, 245-254.	2.3	11
2	The VWF/LRP4/Î±VÎ²3-axis represents a novel pathway regulating proliferation of human vascular smooth muscle cells. Cardiovascular Research, 2022, 118, 622-637.	1.8	22
3	In vitro recovery of FIX clotting activity as a marker of highly functional hepatocytes in a hemophilia B iPSC model. Hepatology, 2022, 75, 866-880.	3.6	12
4	Antithrombotic potential of a singleâ€domain antibody enhancing the activated protein Câ€cofactor activity of protein S. Journal of Thrombosis and Haemostasis, 2022, , .	1.9	0
5	Identification of von Willebrand factor D4 domain mutations in patients of Afroâ€Caribbean descent: In vitro characterization. Research and Practice in Thrombosis and Haemostasis, 2022, 6, e12737.	1.0	1
6	In vivo modulation of a dominantâ€negative variant in mouse models of von Willebrand disease type 2A. Journal of Thrombosis and Haemostasis, 2021, 19, 139-146.	1.9	5
7	Singleâ€domain antibodies targeting antithrombin reduce bleeding in hemophilic mice with or without inhibitors. EMBO Molecular Medicine, 2020, 12, e11298.	3.3	20
8	Camelidâ€derived singleâ€chain antibodies in hemostasis: Mechanistic, diagnostic, and therapeutic applications. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 1087-1110.	1.0	8
9	A hemophilia A mouse model for the in vivo assessment of emicizumab function. Blood, 2020, 136, 740-748.	0.6	32
10	Development and characterization of singleâ€domain antibodies neutralizing protease nexinâ€1 as tools to increase thrombin generation. Journal of Thrombosis and Haemostasis, 2020, 18, 2155-2168.	1.9	6
11	Correction of bleeding in experimental severe hemophilia A by systemic delivery of factor VIII-encoding mRNA. Haematologica, 2020, 105, 1129-1137.	1.7	15
12	Removal of Mannose-Ending Glycan at Asn2118 Abrogates FVIII Presentation by Human Monocyte-Derived Dendritic Cells. Frontiers in Immunology, 2020, 11, 393.	2.2	3
13	A singleâ€domain antibody that blocks factorVIIa activity in the absence but not presence of tissue factor. Journal of Thrombosis and Haemostasis, 2019, 17, 2035-2046.	1.9	1
14	A Thrombin-Activatable Factor X Variant Corrects Hemostasis in a Mouse Model for Hemophilia A. Thrombosis and Haemostasis, 2019, 119, 1981-1993.	1.8	5
15	Targeting protease nexin-1, a natural anticoagulant serpin, to control bleeding and improve hemostasis in hemophilia. Blood, 2019, 134, 1632-1644.	0.6	14
16	Macrophage scavenger receptor SR-AI contributes to the clearance of von Willebrand factor. Haematologica, 2018, 103, 728-737.	1.7	32
17	Kinesin-1 Is a New Actor Involved in Platelet Secretion and Thrombus Stability. Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, 1037-1051.	1.1	17
18	Antigen-selective modulation of AAV immunogenicity with tolerogenic rapamycin nanoparticles enables successful vector re-administration. Nature Communications, 2018, 9, 4098.	5.8	184

#	Article	IF	Citations
19	Protein kinase C signaling dysfunction in von Willebrand disease (p.V1316M) type 2B platelets. Blood Advances, 2018, 2, 1417-1428.	2.5	9
20	A factor VIIIâ€“nanobody fusion protein forming an ultrastable complex with VWF: effect on clearance and antibody formation. Blood, 2018, 132, 1193-1197.	0.6	19
21	Autologous cell/gene therapy approach of hemophilia B using patient specific induced Pluripotent Stem Cells. Journal of Hepatology, 2018, 68, S81-S82.	1.8	0
22	Network-based analysis of omics data: the LEAN method. Bioinformatics, 2017, 33, 701-709.	1.8	29
23	Complex formation with pentraxin-2 regulates factor X plasma levels and macrophage interactions. Blood, 2017, 129, 2443-2454.	0.6	11
24	Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII?. Blood, 2017, 130, 2463-2468.	0.6	197
25	Emerging Therapeutic Strategies in the Treatment of Hemophilia A. Seminars in Thrombosis and Hemostasis, 2017, 43, 581-590.	1.5	22
26	A Novel Single-Domain Antibody Against von Willebrand Factor A1 Domain Resolves Leukocyte Recruitment and Vascular Leakage During Inflammationâ€”Brief Report. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, 1736-1740.	1.1	33
27	Enhanced liver gene transfer and evasion of preexisting humoral immunity with exosome-enveloped AAV vectors. Blood Advances, 2017, 1, 2019-2031.	2.5	90
28	Soluble Siglec-5 associates to PSGL-1 and displays anti-inflammatory activity. Scientific Reports, 2016, 6, 37953.	1.6	26
29	Macrophage receptor SR-AI is crucial to maintain normal plasma levels of coagulation factor X. Blood, 2016, 127, 778-786.	0.6	8
30	A genetically-engineered von Willebrand disease type 2B mouse model displays defects in hemostasis and inflammation. Scientific Reports, 2016, 6, 26306.	1.6	19
31	LIM kinase/cofilin dysregulation promotes macrothrombocytopenia in severe von Willebrand disease-type 2B. JCI Insight, 2016, 1, e88643.	2.3	23
32	Biological outcome and mapping of total factor cascades in response to HIF induction during regenerative angiogenesis. Oncotarget, 2016, 7, 12102-12120.	0.8	6
33	Apoptotic Platelet Events Are Not Observed in Severe von Willebrand Disease-Type 2B Mutation p.V1316M. PLoS ONE, 2015, 10, e0143896.	1.1	4
34	von Willebrand factor biosynthesis, secretion, and clearance: connecting the far ends. Blood, 2015, 125, 2019-2028.	0.6	296
35	Mechanisms and Therapeutic Modulation of the Bleeding Tendency in Genetically-Engineered Von Willebrand Disease Type 2B Mice. Blood, 2015, 126, 3516-3516.	0.6	0
36	Antibody-based prevention of von Willebrand factor degradation mediated by circulatory assist devices. Thrombosis and Haemostasis, 2014, 112, 1014-1023.	1.8	37

#	Article	IF	Citations
37	Liver-Specific Transcriptional Modules Identified by Genome-Wide In Silico Analysis Enable Efficient Gene Therapy in Mice and Non-Human Primates. Molecular Therapy, 2014, 22, 1605-1613.	3.7	71
38	The interaction between factor H and VWF increases factor H cofactor activity and regulates VWF prothrombotic status. Blood, 2014, 123, 121-125.	0.6	63
39	Expression of a structurally constrained von Willebrand factor variant triggers acute thrombotic thrombocytopenic purpura in mice. Blood, 2014, 123, 3344-3353.	0.6	6
40	Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant. Blood, 2013, 121, 3335-3344.	0.6	236
41	VON WILLEBRAND FACTOR ABNORMALITIES STUDIED IN THE MOUSE MODEL: WHAT WE LEARNED ABOUT VWF FUNCTIONS. Mediterranean Journal of Hematology and Infectious Diseases, 2013, 5, e2013047.	0.5	3
42	ON THE VERSATILITY OF VON WILLEBRAND FACTOR. Mediterranean Journal of Hematology and Infectious Diseases, 2013, 5, e2013046.	0.5	36
43	Mutations in the A3 domain of Von Willebrand factor inducing combined qualitative and quantitative defects in the protein. Blood, 2013, 121, 2135-2143.	0.6	25
44	Accelerated uptake of VWF/platelet complexes in macrophages contributes to VWD type 2Bâ€“associated thrombocytopenia. Blood, 2013, 122, 2893-2902.	0.6	68
45	von Willebrand factor mutation promotes thrombocytopathy by inhibiting integrin Î±IIbÎ²3. Journal of Clinical Investigation, 2013, 123, 5071-5081.	3.9	42
46	Identification of Galectin-1 and Galectin-3 as Novel Partners for Von Willebrand Factor. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, 894-901.	1.1	59
47	Factor VIII and von Willebrand factor are ligands for the carbohydrate-receptor Siglec-5. Haematologica, 2012, 97, 1855-1863.	1.7	70
48	Macrophage LRP1 contributes to the clearance of von Willebrand factor. Blood, 2012, 119, 2126-2134.	0.6	99
49	A murine model to characterize the antithrombotic effect of molecules targeting human von Willebrand factor. Blood, 2012, 120, 2723-2732.	0.6	16
50	Thermodynamic Analysis of the Interaction of Factor VIII with von Willebrand Factor. Biochemistry, 2012, 51, 4108-4116.	1.2	17
51	In Vivo Analysis of the Role of O-Glycosylations of Von Willebrand Factor. PLoS ONE, 2012, 7, e37508.	1.1	33
52	Coagulation Factor X Interaction with Macrophages through Its N-Glycans Protects It from a Rapid Clearance. PLoS ONE, 2012, 7, e45111.	1.1	10
53	Determinants of von Willebrand Factor Function. Blood, 2012, 120, SCI-17-SCI-17.	0.6	0
54	Proteolytic antibodies activate factor IX in patients with acquired hemophilia. Blood, 2011, 117, 2257-2264.	0.6	38

#	Article	IF	Citations
55	Mutation and ADAMTS13-dependent modulation of disease severity in a mouse model for von Willebrand disease type 2B. Blood, 2010, 115, 4870-4877.	0.6	60
56	Siglecs as Novel Cellular Partners for Von Willebrand Factor. Blood, 2010, 116, 4306-4306.	0.6	0
57	Correction of Bleeding Symptoms in von Willebrand Factorâ€“Deficient Mice by Liver-Expressed von Willebrand Factor Mutants. Arteriosclerosis, Thrombosis, and Vascular Biology, 2008, 28, 419-424.	1.1	35
58	Hydrolysis of Coagulation Factors by Circulating IgG Is Associated with a Reduced Risk for Chronic Allograft Nephropathy in Renal Transplanted Patients. Journal of Immunology, 2008, 180, 8455-8460.	0.4	22
59	Altered thrombus formation in von Willebrand factorâ€“deficient mice expressing von Willebrand factor variants with defective binding to collagen or GPIbIIIa. Blood, 2008, 112, 603-609.	0.6	67
60	Clearance of von Willebrand factor. Thrombosis and Haemostasis, 2008, 99, 271-278.	1.8	45
61	Role of the Î±-Helix 163-170 in Factor Xa Catalytic Activity. Journal of Biological Chemistry, 2007, 282, 31569-31579.	1.6	23
62	A role for exposed mannosylations in presentation of human therapeutic self-proteins to CD4+ T lymphocytes. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 8965-8970.	3.3	110
63	Paraoxonase-1 expression is up-regulated in Down syndrome fetal liver. Biochemical and Biophysical Research Communications, 2006, 346, 1303-1306.	1.0	6
64	P-selectin glycoprotein ligand 1 and Î²2-integrins cooperate in the adhesion of leukocytes to von Willebrand factor. Blood, 2006, 108, 3746-3752.	0.6	152
65	Catalytic IgG from Patients with Hemophilia A Inactivate Therapeutic Factor VIII. Journal of Immunology, 2006, 177, 1355-1363.	0.4	45
66	Role of the Gla and First Epidermal Growth Factor-like Domains of Factor X in the Prothrombinase and Tissue Factor-Factor VIIa Complexes. Journal of Biological Chemistry, 2003, 278, 10393-10399.	1.6	25
67	Surface Loop 199â€“204 in Blood Coagulation Factor IX Is a Cofactor-dependent Site Involved in Macromolecular Substrate Interaction. Journal of Biological Chemistry, 1999, 274, 29087-29093.	1.6	22
68	Blood Coagulation Factor IX Residues Glu78 and Arg94 Provide a Link between Both Epidermal Growth Factor-like Domains That Is Crucial in the Interaction with Factor VIII Light Chain. Journal of Biological Chemistry, 1998, 273, 222-227.	1.6	41
69	Ca2+ Binding to the First Epidermal Growth Factor-like Domain of Human Blood Coagulation Factor IX Promotes Enzyme Activity and Factor VIII Light Chain Binding. Journal of Biological Chemistry, 1996, 271, 25332-25337.	1.6	65
70	Characterization of Recombinant von Willebrand Factors Mutated on Cysteine 509 or 695. Thrombosis and Haemostasis, 1996, 76, 453-459.	1.8	20